• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Do Dietary Supplements Interfere with Breast Cancer Treatment

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Many people report using dietary supplements during cancer treatment
    • Antioxidants may interfere with the chemotherapy cytotoxicity
  • Ambrosone et al. (Journal of Clinical Oncology, 2019) evaluated the relationship between supplements and breast cancer outcomes

METHODS:

  • Prospective study ancillary to a therapeutic trial
  • Participants
    • Patients with breast cancer enrolled in a trial that evaluated use of cyclophosphamide, doxorubicin, and paclitaxel
  • Self-reported dietary supplement use (at registration and during the trial)
    • Antioxidant supplements: Vitamins A, C, and E; carotenoids | Coenzyme Q10
    • Vitamin B12
    • Multivitamins
    • Iron
  • Study design and data analysis
    • Cox proportional hazards regression
      • Adjusting for clinical and lifestyle variables (e.g., age, tumor characteristics etc.) 
  • Outcomes: Recurrence and survival

RESULTS:

  • 1,134 patients were surveyed
  • Antioxidants (both before and during treatment): Trend towards increased recurrence and death with use
    • Recurrence: Adjusted hazard ratio [aHR] 1.41 (95% CI, 0.98 to 2.04; P = 0.06)
    • Death: aHR, 1.40; 95% CI, 0.90 to 2.18; P = 0.14
    • Relationships with individual antioxidants were weaker (small numbers)
  • Vitamin B12 (both before and during chemotherapy): Significantly associated with decreased disease free survival and survival
    • Poorer disease-free survival: aHR 1.83 (95% CI, 1.15 to 2.92; P < 0.01)
    • Poorer overall survival: aHR 2.04 (95% CI, 1.22 to 3.40; P < 0.01)
  • Iron use (during chemotherapy): was significantly associated with recurrence
    • Recurrence: aHR, 1.79; 95% CI, 1.20 to 2.67; P < 0.01
  • Multivitamin use was not associated with survival outcomes

CONCLUSION:

  • Based on this prospective study, the authors advise caution and “that use of antioxidant supplements during chemotherapy, as well as iron and vitamin B12, may increase the risk of breast cancer recurrence and mortality”

Learn More – Primary Sources:

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Results from the VITAL Trial: Does Vitamin D Reduce Cardiovascular and Cancer Risk in the General Population?
Are Dietary Supplements Associated with Decreased Mortality?
Herb-drug Interactions – How Severe are Potential Adverse Drug Reactions?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site